February 28th is recognized as Rare Disease Day to drive awareness for the millions of people globally that are affected by rare diseases. In recognition of Rare Disease Day, ReAlta would like to highlight and express gratitude to the community of collaborators on our upcoming Phase 2 clinical trial in hypoxic ischemic encephalopathy (HIE), a devastating rare disease affecting newborns. ReAlta’s RLS-0071 drug compound has the potential to change the treatment paradigm for babies born with HIE, a disease that can lead to the death of the child or life-long physical and cognitive disabilities for those that survive. Children’s hospitals, physicians, nurses, and administrators across the U.S., as well as the HIE patient advocacy group Hope For HIE, are collaborating with ReAlta to conduct this trial. In addition to HIE, ReAlta has programs in development to treat patients affected by other rare diseases, which include Severe Asthma, a rare subset of asthma where treatment with standard therapeutics fail.
As part of the #757Strong, local firm SL Nusbaum Realty Co. has partnered with ReAlta to display support for the millions of adults and children affected by rare diseases like HIE, illuminating the Wells Fargo Center in downtown Norfolk with pink, green, blue, and purple, the colors of Rare Disease Day, on February 28, 2023.
Dr. Neel Krishna and Dr. Katherine LaVallee, DVM did an outstanding job leading tours of our lab and offices last...Read More
We want to thank Rep. Elaine Luria and Norfolk Mayor Dr. Kenneth Alexander for helping us celebrate the official opening...Read More
ReAlta Life Sciences is officially part of Team Hope! We are extending our gratitude to the Hope for HIE team...Read More